Company Profile
Werewolf Therapeutics Stock Price, News & Catalysts
- Ticker:
- HOWL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.88 USD (-4.42%)
Close
Last updated: October 1, 2026
20.9M USD
Market cap
Why the stock is moving
As of Oct 1, 2026, HOWL closed down 4.42% at $0.8815. No new same-company headline was identified in the current news window.
Company overview
Conditionally Activated Immunotherapy Company
Werewolf Therapeutics develops immune-stimulating medicines engineered to activate preferentially in diseased tissue. Its strategy is intended to retain the antitumor potency of inflammatory cytokines while limiting systemic exposure and toxicity.
PREDATOR Engineering Platform
The proprietary PREDATOR platform is used to create conditionally activated INDUKINE and INDUCER molecules. These constructs are designed to remain relatively inactive in peripheral tissues and become activated by proteases within the tumor microenvironment.
Clinical-Stage INDUKINE Programs
WTX-124 is a conditionally activated interleukin-2 therapy, while WTX-330 is a conditionally activated interleukin-12 therapy. Both programs were developed for systemic treatment of solid tumors and provide clinical validation for the company's masking and activation approach.
INDUCER Pipeline
Werewolf's newer INDUCER candidates combine conditional immune activation with tumor-targeting components. WTX-1011 targets STEAP1 in prostate cancer, and WTX-2022 targets CDH6 in ovarian and kidney cancers.
Strategic Partnering Orientation
The company is evaluating strategic alternatives and partnership structures to advance its platform and pipeline. Its technology package includes clinical data, engineered cytokine expertise, and preclinical tumor-targeted programs that may be developed with larger oncology partners.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics (HOWL) most recently closed at 0.88 USD, a -4.42% move versus the previous session.
What is the market cap of Werewolf Therapeutics (HOWL)?
Werewolf Therapeutics currently has a market capitalization of 20.9M USD on BioPharmSignal.
What does Werewolf Therapeutics do?
Conditionally Activated Immunotherapy Company Werewolf Therapeutics develops immune-stimulating medicines engineered to activate preferentially in diseased tissue. Its strategy is intended to retain the antitumor potency of inflammatory cytokines while limiting systemic exposure and toxicity. PREDATOR Engineering Platform The proprietary PREDATOR platform...
On which exchange is HOWL stock listed?
Werewolf Therapeutics (HOWL) is associated with NASDAQ, United States, Biopharma.
What is WTX-124?
Clinical-Stage INDUKINE Programs WTX-124 is a conditionally activated interleukin-2 therapy, while WTX-330 is a conditionally activated interleukin-12 therapy.
Which conditions is Werewolf Therapeutics targeting with WTX-124?
Werewolf Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is WTX-330?
Clinical-Stage INDUKINE Programs WTX-124 is a conditionally activated interleukin-2 therapy, while WTX-330 is a conditionally activated interleukin-12 therapy.
What is WTX-1011?
WTX-1011 targets STEAP1 in prostate cancer, and WTX-2022 targets CDH6 in ovarian and kidney cancers.